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Summary
 
An endothelial cell inhibitor was purified from supernatant of an Epstein-Barr virus–immortal-
ized cell line and identified as fragments of calreticulin. The purified recombinant NH
 
2
 
-termi-
nal domain of calreticulin (amino acids 1–180) inhibited the proliferation of endothelial cells,
but not cells of other lineages, and suppressed angiogenesis in vivo. We have named this NH
 
2
 
-
terminal domain of calreticulin vasostatin. When inoculated into athymic mice, vasostatin sig-
nificantly reduced growth of human Burkitt lymphoma and human colon carcinoma. Com-
pared with other inhibitors of angiogenesis, vasostatin is a small, soluble, and stable molecule
that is easy to produce and deliver. As an angiogenesis inhibitor that specifically targets prolifer-
ating endothelial cells, vasostatin has a unique potential for cancer treatment.
Key words: endothelial cells • angiogenesis • cell growth • cancer • antitumor agent
 
T
 
umor growth and invasion into normal tissues are de-
pendent upon an adequate blood supply (1, 2). Agents
that reduce tumor blood supply prevent or delay tumor
formation, and promote the regression or dormancy of es-
tablished tumors. Antibodies against vascular endothelial
growth factor (VEGF),
 
1
 
 which is produced at high levels by
various types of tumors, antibodies against VEGF receptor
2, and soluble VEGF receptors reduced tumor growth in
experimental animal models (3–5). Antibodies to the inte-
grin 
 
a
 
v
 
b
 
3
 
, which is expressed at high levels by angiogenic
blood vessels and permits endothelial cells to interact with
components of the extracellular matrix, disrupted ongoing
angiogenesis on the chick chorioallantoid membrane and
led to the regression of human tumors transplanted into this
site (6–8). Both angiostatin, a fragment of plasminogen (9,
10), and endostatin, a fragment of collagen XVIII (11, 12),
suppressed neovascularization and inhibited the growth of a
variety of experimental tumors. IL-12 (13), the IFN-
 
g
 
 in-
ducible protein-10 (IP-10; 14, 15), the monokine induced
by INF-
 
g
 
 (Mig; 16, 17), a fragment of prolactin (18), syn-
thetic analogues of fumagillin (19), thalidomide (20), plate-
let factor-4 (21), and thrombospondin (22) are multifunc-
tional compounds that inhibited angiogenesis and exerted
antitumor effects.
EBV-immortalized cell lines, which are usually not tu-
morigenic in athymic mice, can promote regression of ex-
perimental Burkitt lymphoma, colon carcinoma, and other
human malignancies established in athymic mice through a
vascular-based process (23, 24). The murine chemokines
IP-10 and Mig, which are induced in the host by EBV-
immortalized cells, can inhibit angiogenesis and contribute
to tumor regression in this model (14, 15, 17). However,
the participation of additional factors was suggested by the
failure of IP-10 and Mig to promote complete tumor re-
gression that is typically induced by EBV-immortalized cells.
A role for factors released by EBV-immortalized cells was
suggested by the observation that conditioned medium from
these cells reduced tumor growth. We sought to identify
factors secreted by EBV-immortalized cells that might di-
rectly inhibit angiogenesis and tumor growth.
 
Materials and Methods
 
Purification of Inhibitory Factor from Conditioned Medium.
 
For pro-
duction of conditioned medium, exponentially growing VDS-O
cells (15) were washed free of serum and cultured (2.0 
 
3
 
 10
 
6
 
1
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g
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MBP, maltose-binding protein; Mig, monokine induced by IFN-
 
g
 
;
VEGF, vascular endothelial growth factor.
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cells/ml) for 48 h in protein-free hybridoma medium–11
(GIBCO BRL, Gaithersburg, MD) supplemented with 5 
 
m
 
g/ml
gentamicin (Sigma Chemical Co., St. Louis, MO). Cells and debris
were removed by centrifugation and sterile filtration (0.45-
 
m
 
m
filters), and 6.0 
 
m
 
g/ml Aprotinin (Sigma Chemical Co.) was
added. After adsorption of nonpolar substances by addition of sil-
ica gel 60 (5 g/liter, EM Science, Gibbstown, NJ), the condi-
tioned medium was filtered, concentrated 15-fold, and ex-
changed into 10 mM Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
, 100 mM NaCl, 0.1
mM imidazole (Sigma Chemical Co.), pH 8.3. The material was
applied to a Chelating Sepharose Fast Flow column (2.5 
 
3
 
 30
cm; Amersham Pharmacia Biotech, Piscataway, NJ) equilibrated
in the same buffer. Bound material was eluted with a 10 mM
Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
, 100 mM NaCl buffer containing 50 mM
imidazole. After exchange into 20 mM Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
buffer, pH 7.8, active fractions were applied to an anion ex-
change Resource Q column (6 ml; Amersham Pharmacia Bio-
tech) equilibrated with the same buffer. Bound fractions were
eluted with a linear gradient of 200 mM to 1.0 M NaCl in
Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
 buffer, pH 6.25. Active fractions were ad-
justed to 1.2 M (NH
 
4
 
)
 
2
 
SO
 
4
 
, and applied to Macro-Prep Methyl
Hydrophobic Interaction Chromatography column (2.5 
 
3
 
 30
cm; Bio-Rad Laboratories, Hercules, CA) equilibrated with 20
mM Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
 buffer containing 1.2 M (NH
 
4
 
)
 
2
 
SO
 
4
 
,
at pH 6.5. Bound material was eluted by a linear decreasing gra-
dient of 1.2–0 M (NH
 
4
 
)
 
2
 
SO
 
4
 
 in 20 mM Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
buffer. Active fractions were loaded onto a Mini Q PC 3.2/3 an-
ion exchange column (Amersham Pharmacia Biotech) equili-
brated with 20 mM Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
 buffer, pH 7.8, and
mounted on a Smart System (Amersham Pharmacia Biotech)
equipped with a superloop. Bound material was eluted by a linear
gradient of NaCl (20 mM to 1.0 M) in the starting buffer.
 
Cell Proliferation Assays.
 
Fetal bovine heart endothelial cells
(FBHE; American Type Culture Collection, Manassas, VA) were
grown through passage 12 (14). Cells were trypsinized, washed,
and cultured (800 cells/well in 0.2 ml DMEM culture medium
with 10% heat inactivated FCS and 5 
 
m
 
g/ml gentamicin) for 5 d.
DNA synthesis was measured by [
 
3
 
H]thymidine deoxyribose up-
take (0.5 mCi/well, 6.7 Ci/mmol; New England Nuclear, Bos-
ton, MA) during the last 20–23 h of culture. Human umbilical
vein endothelial cells (HUVEC), prepared from umbilical cord by
0.1% collagenase II (Worthington Biochemical Corp., Freehold,
NJ) digestion, were grown through passage 5, as described previ-
ously (25). Endothelial cell purity was 
 
.
 
95%, as assessed by stain-
ing with a rabbit antiserum to human Factor VIII–related anti-
gen (DAKO Corp., Carpinteria, CA). Cells were trypsinized
(Trypsin/EDTA; GIBCO BRL), washed, and cultured in tripli-
cate for 3 d (3.5 
 
3
 
 10
 
3
 
 cells/well in 0.2 ml RPMI 1640 culture
medium with 18% heat-inactivated FCS and 18 U/ml porcine hep-
arin). Proliferation was measured by [
 
3
 
H]thymidine uptake during
the last 20–23 h of culture. Human mononuclear cells and mono-
nuclear cells enriched for T or B lymphocytes were used in prolifer-
ation assays in the presence of phytohemagglutinin (Sigma
Chemical Co.), pokeweed-mitogen (Sigma Chemical Co.), or
EBV (B95-8 strain), as described previously (26). Conditions for
proliferation (culture medium, cell density, length of culture)
were optimized for each cell line, including: lymphoblastoid
VDS-O (27); Burkitt lymphoma CA46, BL-41, KK124, Ag876,
SHO (28); prostate adenocarcinoma TSU-Pr1 (from A. Passaniti,
National Institutes of Health, Baltimore, MD); T cell Molt-4;
Hodgkin’s lymphoma Hs445; prostate adenocarcinoma Du145,
and PC3; acute promyelocytic leukemia HL-60; neuroblastoma
SKNMC; lung adenocarcinoma A549; breast adenocarcinoma
MDA-MB-468; Wilms’ tumor SK-NEP-1; colon carcinoma
SW480; melanoma A-375; and human foreskin fibroblasts (H5
68) (all from American Type Culture Collection).
 
Two-dimensional Gel Electrophoresis, SDS-PAGE, and Western
Blotting.
 
Two-dimensional PAGE was performed as described
previously (29). For SDS-PAGE and Western blot analysis, pro-
tein was solubilized in tricine SDS sample buffer (Novex, San Di-
ego, CA), boiled, and run through 10–20% tricine gels. Gels
were stained with Colloidal Coomassie G-250 stain or silver stain
(Novex). Protein was transferred from gel onto Immobilon-P
membranes (Millipore Corp., Bedford, MA). Membranes were
incubated overnight with a rabbit anti–human calreticulin antise-
rum (Affinity Bioreagents Inc., Golden, CO), a rabbit anti–cal-
reticulin N, or a rabbit anti–calreticulin P domain antiserum (30).
Bound antibody was detected with an affinity-purified, peroxi-
dase-linked, donkey anti–rabbit IgG antibody (Amersham Phar-
macia Biotech), and a chemiluminescence detection system (ECL
kit; Amersham Pharmacia Biotech).
 
Protein Sequencing.
 
Protein spots were excised from the Coo-
massie-stained gel and destained. The proteins were digested with
trypsin (Promega Corp., Madison, WI) in the gel (31), and the
resulting fragments were separated by microcapillary HPLC and
analyzed in-line by ion-trap mass spectrometry (model LCQ;
Finnigan Corp., San Jose, CA) (32).
 
Matrigel Angiogenesis Assay.
 
The Matrigel assay was performed as
described previously (14). An aliquot (0.5 ml) of Matrigel (Becton
Dickinson Labware, Bedford, MA), either alone or with desired ad-
ditives, was injected subcutaneously into the midabdominal region
of female BALB/c nude 6–8-wk-old mice. Five mice were injected
with each mixture. After 5–7 d, the animals were killed and the
Matrigel plugs were removed, fixed in 10% neutral buffered forma-
lin solution (Sigma Chemical Co.), and embedded in paraffin. Tis-
sues were sectioned (5-
 
m
 
m thickness), and slides were stained with
Masson’s trichrome. Quantitative analysis of angiogenesis in Matri-
gel plugs used a computerized semiautomated digital analyzer
(model 40-10; Optomax, Hollis, NH). The average area occupied
by cells/1.26 
 
3
 
 10
 
5
 
 mm
 
2
 
 Matrigel field was calculated. Results are
expressed as the mean area occupied by cells per Matrigel field.
 
Production of Recombinant Calreticulin and Recombinant Vasostatin.
 
The expression of the NH
 
2
 
-terminal domain of human calreticu-
lin fused to maltose-binding protein (MBP) in 
 
Escherichia coli
 
 was
reported (33). The induction and purification of the fusion pro-
tein and MBP were accomplished according to New England Bi-
olabs Inc. (Beverly, MA) protocols. Separation of MBP from va-
sostatin was accomplished by cleavage with Factor Xa, as described
previously (33). Cleaved vasostatin was purified from MBP by
anion exchange chromatography using a preequilibrated (20 mM
Tris, pH 8.0, 25 mM NaCl) Resource Q column (Amersham
Pharmacia Biotech), and elution by a stepwise gradient during
which MBP eluted at 100–150 mM NaCl and calreticulin or
vasostatin eluted at 
 
z
 
250 mM NaCl. We have produced 18 lots
of vasostatin with consistent yields of highly purified protein,
with comparable levels of biological activity as assessed by endo-
thelial cell growth assays. All protein lots for in vivo and in vitro
experiments (MBP-vasostatin, MBP, and cleaved vasostatin) were
tested for endotoxin by the Limulus Amebocyte Lysate kinetic-
QCL
 
Ô
 
 assay (BioWhittaker, Walkersville, MD) and were found
to contain 
 
,
 
5 EU/10 
 
m
 
g protein.
 
Mouse Tumor Models.
 
BALB/c nu/nu female 6-wk-old mice
(National Cancer Institute, Frederick, MD), maintained in patho-
gen-limited conditions, received 400 rad (1 rad 
 
5
 
 0.01 Gy) total
body irradiation and 24 h later were injected subcutaneously in
the right abdominal quadrant with exponentially growing human 
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Burkitt lymphoma cells (10
 
7
 
 CA46 cells; 15) or human colon car-
cinoma cell line (6 
 
3
 
 10
 
6
 
 SW-480 cells; American Type Culture
Collection) in 0.2 ml RPMI 1640 medium. In experiments de-
signed to test tumor prevention, immediately after the cells were
inoculated subcutaneously and continuing daily thereafter 6 d/wk,
the mice received subcutaneous injections proximal to the site
of original cell inoculation of test drug or appropriate controls.
Formulation buffer consisted of sterile saline solution containing
50 mg/ml human albumin and 5 mg/ml mannitol (endotoxin 
 
,
 
5
EU/ml). In experiments designed to evaluate effects on established
tumors, cells were inoculated subcutaneously as described above,
and the animals were observed until a tumor appeared. Beginning
at this time, and continuing daily thereafter 6 d/wk, the mice re-
ceived subcutaneous injections of test drug or appropriate con-
trols proximal to the site of original cell inoculation. Tumor size
was estimated (in cm
 
2
 
) twice weekly as the product of two-
dimensional caliper measurements (longest perpendicular length
and width). A subcutaneous mass appearing at or proximal to the
site of cell inoculation was considered a tumor when it measured
at least 0.16 cm
 
2
 
 in surface area and increased in size by at least
0.1 cm
 
2
 
 over the following week.
 
Histology.
 
Tumors and Matrigel plugs were fixed in 10%
neutral buffered formalin solution (Sigma Chemical Co.), embed-
ded in paraffin, sectioned at 4 
 
m
 
m, and stained with hematoxylin
and eosin, or Masson’s trichrome by standard methods.
 
Statistical Analysis.
 
Student’s 
 
t
 
 test was used to evaluate the
significance of group differences; 
 
x
 
2
 
 analysis of 2 
 
3
 
 2 contingency
table and Fisher’s exact test were used to evaluate probability of
association; Wilcoxon rank sums test was used to evaluate differ-
ences in tumor growth curves.
 
Results
 
Culture supernatants of an EBV-immortalized B cell
line, VDS-O, profoundly inhibited the proliferation of pri-
mary HUVEC and FBHE induced by basic fibroblast growth
factor (bFGF) (not shown). Using inhibition of bFGF-
induced endothelial cell proliferation as an assay to monitor
recovery of activity, we purified the inhibitory compounds
from serum-free culture supernatants of the VDS-O cell
line. The biologically active material was analyzed by two-
dimensional gel electrophoresis under reduced conditions
(Fig. 1). Two well-defined polypeptide spots were identi-
fied with molecular masses of 
 
z
 
55 and 
 
z
 
20 kD, and ap-
parent isoelectric point of 4.7 and 5.6, respectively. A series
of poorly defined spots with relative molecular masses
ranging between 30 and 40 kD were also identified. The
well-defined spots were trypsin digested and the tryptic
fragments were analyzed by ion-trap mass spectrometry. By
this method, the 55-kD polypeptide was identified as hu-
man calreticulin, and the 20-kD polypeptide as the light
chain of human ferritin.
A rabbit antiserum to purified recombinant human cal-
reticulin recognized the 55-kD component in a protein gel
blot (Fig. 2 
 
A
 
, SDS-PAGE; Fig. 2 
 
B
 
, immunoblot). It also
recognized the 30–40-kD bands, suggesting that they rep-
resent fragments of calreticulin. Antisera for human calre-
ticulin NH
 
2
 
-terminal (amino acids [aa] 6–19) and COOH-
terminal (aa 382–400) peptides (30) identified the 55-kD
band, confirming its identity to calreticulin. However, only
the antiserum to the NH
 
2
 
-terminal calreticulin peptide re-
acted with the 30–40-kD bands (not shown). We concluded
that the biologically active, purified material contained hu-
man calreticulin, NH
 
2
 
-terminal fragments of calreticulin,
and the light chain of human ferritin.
To assess whether specific fragments of calreticulin might
exhibit inhibitory activity, the NH
 
2
 
-terminal calreticulin
domain, which includes aa 1–180, was produced in E. coli
as a fusion protein of MBP (MBP-calreticulin-N, 33). The
purified MBP-calreticulin-N (Fig. 3, lane 2) and the
cleaved calreticulin-N (Fig. 3, lane 3), but not control MBP
(Fig. 3, lane 1), inhibited the proliferation of FBHE (Fig. 4
and Table 1) and HUVEC (Table 1). We have named this
calreticulin fragment (aa 1–180) vasostatin.
At concentrations of 0.5–2.5 mg/ml, vasostatin had min-
imal effect on: the proliferation of human PBMCs either
unstimulated or stimulated with phytohemagglutinin; B
and T cell–enriched peripheral blood cells stimulated with
EBV and pokeweed mitogen, respectively; human foreskin
fibroblasts (H568); Burkitt lymphoma cells; lymphoblastoid
cells; T cells; neuroblastoma cells (SK-N-MC); lung carci-
noma cells (A-549); breast adenocarcinoma cells (MDA-
MB-468); acute promyelocytic leukemia cells (HL-60);
prostate adenocarcinoma cells (Tsu-Pr1, PC-3, Dul45);
Hodgkin’s lymphoma cells (Hs445); colon adenocarcinoma
cells (SW-480); Wilms’ tumor cells (SK-NEP-1); and mel-
anoma cells (A-375) (not shown).
The murine Matrigel assay (14) was used to evaluate the Figure 1. Two dimensional gel electrophoresis of purified material.
Figure 2. PAGE and Western
blotting of purified cell line su-
pernatant. Purified material was
electrophoresed on a tricine gel
containing 10–20% acrylamide.
After electrophoresis, one lane
(lane  A) was stained with Colloi-
dal Coomassie, and the other
(lane  B) was blotted onto transfer
membrane and reacted overnight
with a rabbit anti–human calreti-
culin antiserum (antibody PA3-
900). Bound antibody was de-
tected with an affinity-purified, peroxidase-linked, donkey anti–rabbit
IgG antibody and a chemiluminescence detection system.2352 Vasostatin Is a Novel Inhibitor of Angiogenesis
effects of vasostatin on angiogenesis in vivo. When added to
Matrigel at concentrations of 5–10 mg/ml, MBP-vasostatin
and vasostatin (cleaved and purified from MBP-vasostatin)
inhibited bFGF-induced neovascularization (Table 2).
Vasostatin was first tested for its ability to prevent growth
of human Burkitt lymphomas in athymic mice. In a repre-
sentative experiment (of three performed), MBP-vasostatin
was injected for 18 d, at which time all animals with tumors
were killed. The remaining mice continued treatment until
tumor formation (Fig. 5 A). By day 18, 4 of 12 animals
treated with MBP-vasostatin (60 mg/mouse) as opposed to
12 of 12 control-treated animals had developed a tumor (P 5
0.0013). The mean (6SD) weight of tumors in the control
group (0.43 6 0.2 g) was greater than the weight of tumors
from vasostatin-treated animals (0.21 6 0.05 g), but the
difference did not reach statistical significance (P 5 0.059).
With continued treatment, three additional tumors ap-
peared on days 23, 64, and 91, but the remaining five ani-
mals remained tumor free as of day 160. We then com-
pared the effects of vasostatin at two doses, 20 and 100 mg/
mouse (Fig. 5 B). After 18 d of treatment, none of the mice
(0 of 9) inoculated with MBP-vasostatin at the dose of 100
mg per mouse had developed a tumor. All (6 of 6) mice in-
oculated with buffer alone (P 5 0.0002) and 3 of 5 mice
inoculated with MBP-vasostatin at the dose of 20 mg/
mouse developed a tumor (not significantly different from
control, P 5 0.018), indicating a dose effect. Treatment
was continued unchanged until tumors appeared. As of day
44, only two tumors had appeared in the group treated
with the highest dose.
We tested the effects of vasostatin on established human
colon carcinoma and Burkitt lymphoma. The rate of colon
carcinoma growth was significantly reduced in the group
treated with vasostatin at a dose of 100 mg/mouse (12 mice)
compared with the control group (10 mice) treated with
formulation buffer alone (P 5 0.0003, Fig. 5 C). All tumors
were removed on day 39 of treatment. The mean (6SD)
weight of colon carcinoma tumors in the control group
(3.04 6 0.6 g) was significantly (P 5 0.0004) greater than
the weight of tumors from vasostatin-treated animals (1.48
6 0.64 g). In another experiment, the rate of Burkitt lym-
phoma growth (Fig. 5 D) was also significantly reduced in
the group (9 mice) treated with vasostatin at a dose 200 mg/
mouse compared with the controls (10 mice) treated with
formulation buffer alone or MBP (P 5 0.003). Tumors were
removed on day 48. The mean weight of Burkitt tumors in
the control group (6.89 6 2.6 g) was significantly greater
(P 5 0.0005) than the mean weight of tumors treated with
vasostatin (2.74 6 0.6 g). There was no evidence of local
or systemic toxicity in vasostatin-treated animals.
Figure 3. PAGE of recombi-
nant purified proteins (lane 1,
MBP; lane 2, MBP-vasostatin
[calreticulin N-domain]; lane 3,
vasostatin). Recombinant MBP
and MBP-vasostatin were puri-
fied as described. Separation of
MBP from vasostatin was accom-
plished by cleavage with Factor
Xa. Cleaved vasostatin was sepa-
rated from MBP by anion ex-
change chromatography. Purified
proteins were analyzed by elec-
trophoresis on a 10–20% tricine
gel and stained with Colloidal
Coomassie G-250.
Figure 4. Inhibition of FBHE proliferation by MBP-vasostatin (calre-
ticulin N-domain). FBHE were grown through passage 12. Cells were
trypsinized, washed, and cultured (800 cells/well in 0.2 ml DMEM cul-
ture medium with 10% heat-inactivated FCS and 5 mg/ml gentamicin)
for 5 d with or without bFGF (25 ng/ml). DNA synthesis was measured
by [3H]thymidine deoxyribose uptake during the last 20–23 h of culture. (A)
Dose dependency of MBP-vasostatin inhibition. (B) Effects of 1 mg/ml
MBP-vasostatin and MBP (average results of nine experiments).
Table 1. Inhibition of Endothelial Cell Proliferation by Vasostatin
Additions to culture Proliferation Inhibition
mean cpm/culture %
*None 142
bFGF 32,493
MBP-vasostatin 17,930 44.8
MBP 34,363
Vasostatin 13,231 59.3
‡None 4,210
bFGF 28,050
Vasostatin 9,864 64.8
HUVEC or FBHE were cultured in medium alone or in medium sup-
plemented with bFGF (25 ng/ml). Recombinant purified MBP-vaso-
statin (1 mg/ml), vasostatin (1 mg/ml), or MBP (1 mg/ml) were added
to cultures.
*Cultures containing HUVEC. HUVEC prepared from umbilical cord
by 0.1% collagenase II digestion, were grown through passage 5. Endo-
thelial cell purity was .95%, as assessed by staining with a rabbit antise-
rum to human Factor VIII–related antigen. Cells were trypsinized,
washed, and cultured in triplicate for 3 d (3.5 3 103 cells/well in 0.2 ml
RPMI 1640 culture medium with 18% heat-inactivated FCS and 18
U/ml porcine heparin). Proliferation was measured by [3H]thymidine
uptake during the last 20–23 h of culture. The results reflect the mean
of triplicate cultures; SDs are within 10% of the mean. Results are rep-
resentative of five experiments performed.
‡Cultures containing FBHE, as described in the legend to Fig. 3. The
results reflect the mean of three experiments.2353 Pike et al.
lin, which includes aa 1–180, is the most conserved domain
among the calreticulins so far cloned and has no homology
to other protein sequences (34, 35). Although it does not
bind calcium, it can bind the cytoplasmic domain of a sub-
units of integrins regulating cell attachment (37), can inter-
Table 2. Effects of Vasostatin on Angiogenesis In Vivo
Additions to Matrigel
Mean surface area
occupied by cells Inhibition
mm2/1.26 3 105 mm2 %
None 649
bFGF 11,544
bFGF 1 MBP-vasostatin
(10 mg/ml) 4,539 61
bFGF 1 MBP-vasostatin
(5 mg/ml) 5,286 54
bFGF 1 MBP (10 mg/ml) 9,186 20
None 487
bFGF 14,472
bFGF 1 MBP-vasostatin
(5 mg/ml) 4,989 66
bFGF 1 vasostatin
(5 mg/ml) 4,638 68
MBP (5 mg/ml) 13,472 7
Mice (BALB/c nude, 6–8-wk-old, five mice per group) were injected
subcutaneously into the midabdominal region with Matrigel alone;
Matrigel plus bFGF; or Matrigel plus bFGF (150 ng/ml) plus MBP-vaso-
statin, MBP, or vasostatin (in all cases, total injection volume 0.5 ml).
Plugs were removed after 5–7 d, fixed in 10% neutral buffered formalin
solution, embedded in paraffin, and histologic sections were stained
with Masson’s trichrome. The results reflect the mean surface area (ex-
pressed in mm2) occupied by cells within a circular surface area of 1.26 3
105 mm2. All lots of MBP and MBP-vasostatin contained ,5 U endo-
toxin/10 mg protein as determined by the Limulus Amebocyte Lysate
assay.
Histology showed that tissue from control tumors and
tumors treated with vasostatin were indistinguishable with
respect to morphology of tumor cells and the number of
mitoses. However, vasostatin-treated tumors occasionally
displayed changes in the tumor vasculature, including inti-
mal and medial thickening, focal fibrinoid necrosis of the
vessel wall, and occasional infiltration with neutrophils, his-
tiocytes, and lymphocytes (Fig. 5, E and F). These alter-
ations were absent from parallel tumors of control animals.
No abnormalities were noted on gross and histological ex-
amination of liver, spleen, kidneys, heart, lung, and lymph
nodes from vasostatin-treated animals.
Discussion
These results show that vasostatin, an NH2-terminal
fragment of human calreticulin, can inhibit endothelial cell
proliferation in vitro, suppress neovascularization in vivo,
and prevent or reduce growth of experimental tumors.
Calreticulin, a ubiquitous and highly conserved protein
originally identified in skeletal muscle sarcoplasmic reticu-
lum, serves as one of the major storage depots for calcium
ions within the endoplasmic reticulum and participates in
calcium signaling (34–36). The NH2-domain of calreticu-
Figure 5. Inhibition of tumor growth by vasostatin. Burkitt lymphoma
cells (CA46 cell line, 107 cells in 0.2 ml RPMI 1640 medium) were inoc-
ulated subcutaneously into BALB/c athymic mice, 6 wk old. Beginning
on the day of cell inoculation and continuing thereafter daily (6 d/wk),
mice were inoculated subcutaneously proximal to the site of cell inocula-
tion with either formulation buffer (sterile water containing 0.5% manni-
tol, 5% human albumin, and 1% sodium chloride) or test protein (A and
B). (A) 12 mice were inoculated with control purified MBP (40 mg/d 3
18 d), and 12 mice were inoculated with MBP-vasostatin (60 mg/day 3
18 d); all mice with tumor (12 treated with MBP and 4 treated with
MBP-vasostatin) were killed on day 18. The remaining mice were ob-
served. (B) Six mice were treated with formulation buffer alone (0.1 ml/d 3
22 d), five mice were treated with 20 mg/d 3 22 d purified MBP-vasostatin
(open triangle), and nine mice were treated with 100 mg/d 3 22 d puri-
fied MBP-vasostatin (filled circle). (C) Mice (BALB/c athymic mice, 6 wk
old) were inoculated subcutaneously with the human colon carcinoma
cell line (SW-480, 6 3 106 cells/mouse in 0.2 ml RPMI medium). After
a tumor appeared (at least 130 mm2 in size), 12 mice were treated with
MBP-vasostatin (100 mg/d, 6 d/wk, 100 ml/dose, 3 36 d), and 10 mice
were inoculated with formulation buffer (100 ml 3 36 d). Tumor size was
estimated as the product of two-dimensional caliper measurements. (D)
Mice were inoculated subcutaneously with the human Burkitt lymphoma
cell line CA46 as described above. After a tumor appeared (at least 130
mm2 in size), 9 mice were treated with MBP-vasostatin (200 mg/d, 6 d/wk,
100 ml/dose 3 46 d) and 10 mice were treated with formulation buffer
alone (100 ml 3 46 d). (E and F) Histology of Burkitt tumors after treat-
ment with MBP-vasostatin depicting a characteristic vessel with fibrinoid
necrosis and surrounding neutrophil infiltration (E), and a vessel with in-
timal and medial thickening (F); Hematoxylin-eosin stain; 363.2354 Vasostatin Is a Novel Inhibitor of Angiogenesis
act with the nuclear receptors for glucocorticoid, androgen,
and retinoic acid, regulating their binding to DNA (38), and
can, once phosphorylated, bind stem-loop structures at the
39-end of rubella virus genomic RNA contributing to virus
replication (30, 33). However, neither calreticulin nor the
NH2-domain of calreticulin has been shown previously to in-
hibit endothelial cell growth, angiogenesis, or tumor growth.
Vasostatin directly and specifically inhibited endothelial
cell growth but had minimal effect on the growth of other
cells. Previously, calreticulin was reported to bind specifi-
cally and reversibly to endothelial cells in vitro with a Kd of
z7.4 nM, and to localize selectively to the vascular endo-
thelium in vivo. It was also found to promote nitric oxide
release from endothelial cells (39). Although its role in an-
giogenesis is controversial, nitric oxide was reported to
suppress angiogenesis and endothelial cell migration (40,
41). We do not know the mechanism by which vasostatin
inhibits endothelial cell growth. Preliminary experiments in
vitro have failed to support a role of nitric oxide as a medi-
ator of growth inhibition by vasostatin. However, we be-
lieve that inhibition of endothelial cell proliferation is cen-
tral to suppression of angiogenesis and tumor growth by
vasostatin. In the Matrigel angiogenesis assay, plugs with
vasostatin contained significantly fewer endothelial cells
compared with control plugs. In vitro, tumor cells were
not growth inhibited by vasostatin, and in vivo, tumor tis-
sues from vasostatin-treated mice were histologically similar
to controls, suggesting that vasostatin acts indirectly on tu-
mor cells. In vasostatin-treated animals, vessels distant from
the tumor appeared normal, and even the established tu-
mor vasculature had limited evidence of vasostatin-induced
damage. This suggests that the antitumor effects of vasosta-
tin are related to inhibition of new vessel formation rather
than to a toxic effect on established tumor vascular structures.
Tumor regression induced by EBV-immortalized cells is
characterized by reduced tumor growth, extensive tumor
tissue necrosis leading to complete tumor regression, and
vascular damage (17, 23, 24). The chemokines IP-10 and
Mig, induced but not secreted by EBV-immortalized cells,
contributed to tumor regression in this model by promot-
ing extensive tumor tissue necrosis and intravascular throm-
bosis (15, 17). Exogenous IL-12 exerted similar effects due
to its induction of IP-10 and Mig (42, 43). However, IP-10
and Mig treatment minimally reduced tumor size, and tu-
mors eventually grew (15, 17). We now show that vasosta-
tin significantly reduced tumor growth without causing tu-
mor tissue necrosis or extensive intravascular thrombosis.
Therefore, it will be interesting to test the antitumor effects
of vasostatin treatment combined with IP-10, Mig, or IL-12.
A number of favorable features set vasostatin apart from
other inhibitors of angiogenesis. Compared with thrombo-
spondin, angiostatin and endostatin, vasostatin is a small,
soluble, and stable molecule that is easy to produce and de-
liver. We have produced 18 independent batches of re-
combinant vasostatin, with consistent yields of biologically
active, purified protein that were stable for .9 mo in aque-
ous solution. By contrast, endostatin produced in E. coli
was insoluble, and was thus used as a suspension for in vivo
studies (11). Angiostatin was produced by proteolysis of
human plasminogen purified from plasma (10). Thrombo-
spondin was purified from human platelets (44). Thus, un-
like vasostatin, these molecules may represent manufactur-
ing challenges. In addition, the effective dose of vasostatin
in mice was 4–10-fold lower than the effective doses of en-
dostatin or angiostatin (10, 11). Thrombospondin, inhibi-
tory at nanomolar concentrations, promotes endothelial
cell migration at higher concentrations (45). A requirement
for large drug doses or complex dose–function relationships
may add cost and challenges to product development. Fur-
thermore, although vasostatin specifically targeted prolifer-
ating endothelial cells, other inhibitors such as thrombo-
spondin appear to have more complex activities (44).
Angiostatin and endostatin may not only inhibit proliferat-
ing endothelial cells, but may also be toxic for the estab-
lished tumor vasculature (46).
As yet, we do not know the full spectrum of tumors that
are responsive to the angiostatic effects of vasostatin, the
optimal vasostatin dose and regimen, or whether spontane-
ous tumors in their natural sites are responsive to vasostatin.
We report that vasostatin, the NH2-domain of calreticulin,
is a potent and selective endothelial cell growth inhibitor that
suppresses angiogenesis and tumor growth. These results
emphasize the potential benefits of drugs that target angio-
genesis in the prevention and treatment of human cancer.
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